Abi Millar

All Articles

Ferring and subsidiary Rebiotix are developing a microbiota-based live biotherapeutic, RBX2660, against recurrent C. diff.

By Abi Millar

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive.

Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday.

Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday.

The pharmaceutical industry's most comprehensive news and information delivered every month.

I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy

SUBSCRIBED

THANK YOU